@BReinfeld

MSKCC Oncology Fellow, Former Vanderbilt MSTP/UCLA Intern. Bass player in the CheckPoints. Physician-scientist studying metabolism. Views are my own! 🏳️‍🌈🩺

 Manhattan, NY
shorturl.at/IKRST
Joined February 2012
  • Tweets3.9K
  • Following1.3K
  • Followers1.5K
195Media
Include

Only show posts containing:

Exclude

Hide posts containing:

Time range
-
Minimum likes
Replying to @StrijbosMichiel @drenriquegrande @DrIacovelli
That trial only enrolled patients within 1 year of diagnosis,LS022- two years. You can argue these oligomet recurrences later are a diff biology (see IMDC criteria). This data is helpful for a relatively common clinical scenario.
12
Replying to @NotGenentech @montypal @AlbigesL @KoenvdMijn @YujiMiura5 @BraunMDPhD @DrChoueiri @VincentWenxinXu @KidneyCancer @KidneyCancerDoc @kidneycan @Jani_Chinmay @batraatulonc @SuyogCancer @Uromigos @neerajaiims
Chemo doesn’t really work in HCC either. Both diseases have been clinically revolutionized by VEGFi and IO. They were deemed recalcitrant in the age of chemo. Melanoma is another chemo resistant disease and ADCs are not making huge traction…
1
19
Dr. Brad Reinfeld, MD PhD retweeted
Hidehito HORINOUCHI
@HHorinouchi18h
🔥Krascendo 1: Divarasib vs sotorasib/adagrasib in previously treated KRAS G12C-mutated NSCLC 🆙 @NEJM #ESMO26 ☑Phase 3 RCT; N=338; mFU 14.3 mo 🎯mPFS 9.8 vs 5.7 mo (HR 0.58, p<0.001); mOS 17.7 vs 12.0 mo (HR 0.56, p<0.001); ORR 58.4 vs 32.3% 🎙 @FSkoulidis #LCSM @OncoAlert @Larvol @KRASKickers nejm.org/doi/full/10.1056/NE…
Hidehito HORINOUCHI
@HHorinouchiOct 25
🆙#ESMO26 Presidential Symposium II: #LCSM 🔥Krascendo 1: Efficacy and Safety of Divarasib (Diva) vs Sotorasib (Soto) or Adagrasib (Ada) in Previously Treated Locally Advanced or Metastatic KRAS G12C-Mutated NSCLC 🎙️ @FSkoulidis 🔢LBA5 🎯Significantly Improved PFS (9.8 vs 5.7mo, HR 0.58; n=338) and OS (17.7 vs 12.0mo, HR 0.56, p=0.0005) 🎯ORR 58.4% vs 32.3% 🎯Discontinuation Due to TRAEs 4.8% vs 11.7% ☑️NCT06497556 🔗 cslide.ctimeetingtech.com/es… @OncoAlert @Larvol @myESMO @IASLC @KRASKickers
4
10
622
Replying to @montypal @AlbigesL @KoenvdMijn @YujiMiura5 @BraunMDPhD @DrChoueiri @VincentWenxinXu @KidneyCancer @KidneyCancerDoc @kidneycan @Jani_Chinmay @batraatulonc @SuyogCancer @Uromigos @neerajaiims
This may be my overly naive prospective, but RCC patients have never benefited from chemo. So why would an ADC (with a chemo payload) work? Novel ADCs with conjugated immune adjuvants, metabolic inhibitors may be more likely to work than chemo in RCC, no?
1
2
104
Replying to @DrIacovelli
@DrIacovelli with phase 2 #PEPE trial - pembrolizumab w met directed treatment vs MDT in oligomet #kidneycancer — meets 1o PFS endpoint. Congrats on well done IIT. My practice is pembro after consolidative tx & great to see prospective supporting data. @oncoalert #ESMO26 @myESMO
14
17
774
Dr. Brad Reinfeld, MD PhD retweeted
Yu-Wei Chen, MD, MS
@YuWeiChenMDOct 23
Important data from #ESMO2026 in #mCRPC: 🧬 56% of HRR alterations detected by liquid biopsy were predicted to originate from clonal hematopoiesis (CH). ⚠️ Patients with CH-only HRR alterations did not appear to benefit from PARPi monotherapy. Distinguishing CH from tumor-derived mutations is critical for treatment selection. #ProstateCancer @EAntonarakis @urotoday @PCF_Science @OncoAlert
1
6
1
20
1,410
Dr. Brad Reinfeld, MD PhD retweeted
Cancer Discovery@CD_AACROct 24
Now online: Peripheral Blood as the Sole Source of Cancer Neoantigen and Reactive T-cell Discovery doi.org/10.1158/2159-8290.CD…
11
16
1,423
Dr. Brad Reinfeld, MD PhD retweeted
Martín Angel@Martin_AngelMDOct 24
Presidential symposium 1️⃣!! Interpath-001: adjuvant INT (intismeram) plus pembro impact in RFS & DMFS for stage II-IV resectable melanoma #ESMO26 @ProfGLongMIA @myESMO #personalizedmedicine – at Madrid, Spain
12
13
860
Dr. Brad Reinfeld, MD PhD retweeted
Cell@CellCellPressOct 24
Now online! A bioavailable GPX4 inhibitor for ferroptosis induction in vivo and tumor suppression dlvr.​it/TW2szc
3
23
2
104
11,476
Dr. Brad Reinfeld, MD PhD retweeted
Anirban Maitra@Aiims1742Oct 24
From #ESMO26 & @NEJM Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer nejm.org/doi/full/10.1056/NE… Practice changing data for a terrible disease with hazard ratios that are unequivocal.

Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer | NEJM

Patients with extensive-stage small-cell lung cancer have poor outcomes, with a median overall survival of approximately 12 to 13 months. Tarlatamab (a bispecific T-cell engager targeting delta-lik...

nejm.org
1
9
1
39
3,187
Dr. Brad Reinfeld, MD PhD retweeted
Tennessean@TennesseanOct 22
Jefferson Street Sound Museum founder Lorenzo Washington dies at 83 tennessean.com/story/news/lo…

Jefferson Street Sound Museum founder Lorenzo Washington dies at 83

Lorenzo Washington, the founder and curator of the nonprofit Jefferson Street Sound Museum dedicated to preserving the rich history of Nashville’s Black music scene, has died after a short battle...

tennessean.com
5
1
11
1,646
Dr. Brad Reinfeld, MD PhD retweeted
Nieves Martinez Lago MD PhD
@DraMartinezLagoOct 22
🧬 NICHE-2 | Phase II | dMMR colon cancer 🇳🇱 👥 111 pts | Nivo + ipi → surgery 🎯 3-y DFS 100% 📈 5-y OS 100% 🩸 ctDNA clearance 82% pre-op ✅ All ctDNA− post-op ⚠️ Single-arm trial 💡 Remarkable long-term outcomes! 🔗 doi.org/10.1016/S0140-6736(2… @OncoAlert
4
32
3
74
7,973
Dr. Brad Reinfeld, MD PhD retweeted
Joel M. Topf, MD FACP
@kidney_boyOct 22
97% risk reduction for composite outcome!
1
2
2
23
7,181
Replying to @S_Corcoran
Just imagine snow
59
Dr. Brad Reinfeld, MD PhD retweeted
Hematopoiesis News
@Hema_NewsOct 21
🥼Scientists have developed a massively parallel single-cell #CRISPR screening platform in primary human #hematopoietic stem and progenitor cells, capturing known associations and functional annotation of regulator-phenotype relationships. Read more in @CellStemCell: bit.ly/4dLvplB.
8
24
1,631
Dr. Brad Reinfeld, MD PhD retweeted
Journal for ImmunoTherapy of Cancer
@jitcancerOct 20
New #JITC article: "Site-specific metabolic and hypoxia-associated profiles in metastatic melanoma" doi.org/10.1136/jitc-2026-01…
2
2
3
586
Dr. Brad Reinfeld, MD PhD retweeted
Hematopoiesis News
@Hema_NewsOct 16
Drs. Jennifer Marvin-Peek & Farhad Ravandi summarize the evolving therapeutic landscape of #AML, including current intensive and lower-intensity treatment backbones, approved molecularly targeted therapies, and emerging investigational strategies. 💊 bit.ly/4dI8nMo | @SpringerNature #OpenAccess #AcuteMyeloidLeukemia
1
7
436
Dr. Brad Reinfeld, MD PhD retweeted
Nico Gagelmann
@NicoGagelmannOct 13
Really excited to share the first comprehensive study of germline DDX41 in MDS undergoing transplantation in @BloodPortfolio . Grateful to Coleman Lindsley, germline brain Chris Reilly @DanaFarber and whole team from @CIBMTR 🙏❤️ ashpublications.org/blood/ar…

Germline DDX41 defines a distinct subgroup in MDS undergoing transplantation with reduced relapse...

Key Points. Germline DDX41 is independently associated with lower relapse and improved DFS in MDS undergoing allogeneic transplantation.No excess non-relap

ashpublications.org
5
23
1
99
8,337
Dr. Brad Reinfeld, MD PhD retweeted
Ed Reznik@EdReznikOct 12
After many years of effort, deliberation, excitement, angst, joy, and Wednesday afternoon lab lunches, our group's first manuscript on cachexia, led by Venise Jan Castillon, Amy Xie, and really our whole lab nature.com/articles/s41591-0… @NatureMedicine

A health-system-scale, episode-resolved multimodal atlas of cancer cachexia

Nature Medicine - Using longitudinal data from 52,236 patients with cancer, this study created a multimodal atlas of cancer cachexia, demonstrating that weight loss episodes are linked to systemic...

nature.com
9
42
5
129
15,620
Dr. Brad Reinfeld, MD PhD retweeted
BWFUND@BWFUNDOct 9
From nature reviews cancer - Mapping the functional dark proteome in cancer buff.ly/EyN6QCH #bwfcams

Mapping the functional dark proteome in cancer

Nature Reviews Cancer - The dark proteome encompasses previously undiscovered and uncharacterized protein molecules derived from alternative genomic loci or altered RNA translation. In this...

nature.com
1
503
Load more